Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies Editorial
| Authors: | Dholakia, J.; Liang, M. I.; Aviki, E. M. |
| Title: | Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies |
| Keywords: | cancer chemotherapy; cancer survival; treatment outcome; bevacizumab; cisplatin; doxorubicin; gemcitabine; paclitaxel; cancer patient; endometrium cancer; clinical practice; carboplatin; ovary cancer; maintenance therapy; editorial; docetaxel; cost control; drug cost; health care cost; health insurance; medicare; patient care; adjuvant chemotherapy; uterine cervix cancer; long term care; clinical decision making; immunomodulating agent; trastuzumab; vasculotropin antibody; cost benefit analysis; female genital system; female genital tract cancer; human; risk model; pembrolizumab; alternative payment model; oncology care first model; oncology care model |
| Journal Title: | Gynecologic Oncology |
| Volume: | 165 |
| Issue: | 1 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-04-01 |
| Start Page: | 11 |
| End Page: | 13 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2022.02.003 |
| PUBMED: | 35168821 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Editorial -- Export Date: 25 April 2022 -- Source: Scopus |
